Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)

NCT06839235 is registered in ClinicalTrials.gov with Arbor Biotechnologies as lead sponsor.

NCT NCT06839235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06839235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)
Lead sponsor
Arbor Biotechnologies
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 16, 2025
Completion date
February 28, 2043
Enrollment
23 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

primary hyperoxaluria type 1 (ph1)